Literature DB >> 12870567

REM sleep effects as a biomarker for the effects of antidepressants in healthy volunteers.

B Rijnbeek1, S J de Visser, K L Franson, A F Cohen, J M A van Gerven.   

Abstract

The potential use of rapid eye movement (REM) sleep effects as a biomarker for the therapeutic effects of antidepressants in healthy volunteers is reviewed. A literature search was performed to select studies investigating the effects of antidepressants on REM sleep. To assess the specificity of REM sleep effects as a biomarker, the effects of other central nervous system drugs on REM sleep were also investigated. A significant REM sleep reduction was shown for 16 of 21 investigated antidepressants after single-dose (mean reduction 34.1%) and for 11/13 drugs after multiple-dose administration (mean reduction 29.2%). The median increase in REM latency was approximatety 60% after single- or multiple-dose administration. REM sleep effects were linearly normalized to therapeutic doses, by dividing the REM sleep effect by the investigated dose and multiplying by the therapeutic dose. Normalized REM sleep effects were highly variable (range -27.0% to 81.8% for REM sleep; range -17.0% to 266.3% for REM latency) and demonstrated no relationship with relevant pharmacological properties of the investigated drugs. No quantifiable dose-response relationship could be constructed after single and multiple dose administration. REM sleep effects were not specific for antidepressants. Benzodiazepines, for example, caused an average dose normalized REM sleep reduction of 8.7% and a median 8.6% increase of REM latency. This review demonstrates that although REM sleep effects occur with most of the antidepressants, it is by itself of limited value as a biomarker for antidepressant action. The specificity for antidepressants is limited, and it does not show a quantitative dose-response relationship to antidepressant agents. This is at least partly due to the complex relationships between drug pharmacokinetics and the variable time course of REM and other sleep stages throughout the night. Models that take these complex relationships into account may provide more comprehensive and quantifiable results.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12870567     DOI: 10.1177/0269881103017002008

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  9 in total

1.  Mirtazapine-induced nightmares.

Authors:  Maju Mathews; Biju Basil; Harun Evcimen; Babatunde Adetunji; Sunil Joseph
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2006

2.  Mirtazapine induced nightmares in an adult male.

Authors:  Amit Dang; Gaurav Garg; Padmanabh V Rataboli
Journal:  Br J Clin Pharmacol       Date:  2008-11-05       Impact factor: 4.335

Review 3.  Pharmacokinetic and pharmacodynamic data to be derived from early-phase drug development: designing informative human pharmacology studies.

Authors:  Adam Cohen
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 4.  Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects.

Authors:  G J H Dumont; S J de Visser; A F Cohen; J M A van Gerven
Journal:  Br J Clin Pharmacol       Date:  2005-05       Impact factor: 4.335

5.  Ventromedial prefrontal cortex regulates depressive-like behavior and rapid eye movement sleep in the rat.

Authors:  Celene H Chang; Michael C Chen; Mei Hong Qiu; Jun Lu
Journal:  Neuropharmacology       Date:  2014-07-15       Impact factor: 5.250

6.  Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 2, pharmacological interactions in rodents suggest a role of serotonin-3 receptor antagonism.

Authors:  Steven C Leiser; Deborah Iglesias-Bregna; Ligia Westrich; Alan L Pehrson; Connie Sanchez
Journal:  J Psychopharmacol       Date:  2015-07-14       Impact factor: 4.153

7.  Multimodal antidepressant vortioxetine increases frontal cortical oscillations unlike escitalopram and duloxetine--a quantitative EEG study in rats.

Authors:  S C Leiser; A L Pehrson; P J Robichaud; C Sanchez
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

8.  Effect of TAAR1/5-HT1A agonist SEP-363856 on REM sleep in humans.

Authors:  Seth C Hopkins; Nina Dedic; Kenneth S Koblan
Journal:  Transl Psychiatry       Date:  2021-04-20       Impact factor: 6.222

9.  Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep-wake cycle architecture.

Authors:  Amandine Descamps; Colette Rousset; Mark J Millan; Mark Millan; Michael Spedding; Philippe Delagrange; Raymond Cespuglio
Journal:  Psychopharmacology (Berl)       Date:  2009-04-16       Impact factor: 4.530

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.